GlassScriptPhysician profile
Scott R Holmes
NPI 1194003368
$5,777.55
in general payments reported to CMS, 2019-2025
31 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $543 · 2021: $649 · 2022: $818 · 2023: $1,254 · 2024: $1,030 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,208.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.99 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Celgene Corporation | $480.96 | 2022-2024 | Zeposia |
| Pfizer INC. | $378.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.40 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $242.21 | 2019-2024 | Dificid |
| Genzyme Corporation | $182.91 | 2022-2025 | |
| Janssen Biotech, INC. | $168.81 | 2019-2024 | Simponi Aria, Stelara, Simponi |
| Ardelyx, INC. | $148.77 | 2023-2025 | Ibsrela |
| Endogastric Solutions, INC | $132.13 | 2019 | |
| Celltrion USA INC. | $112.48 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $110.56 | 2020-2024 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $99.64 | 2023 | Zeposia |
| Amgen INC. | $89.41 | 2020-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $69.29 | 2020-2025 | Suflave, Sutab |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66.13 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $63.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $59.47 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $56.68 | 2020-2025 | Sucraid |
| Olympus America INC. | $55.36 | 2019 | |
| Gilead Sciences, INC. | $46.38 | 2019 | |
| Redhill Biopharma INC. | $32.65 | 2020 | |
| Organon LLC | $31.14 | 2022-2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $30.14 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $29.99 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $28.79 | 2022-2025 | Riteclip |
| Ironwood Pharmaceuticals, INC | $27.80 | 2021-2022 | |
| Mylan Institutional INC. | $15.68 | 2023 | |
| Digestive Care, INC. | $15.21 | 2020 | |
| Alfasigma USA, INC. | $13.28 | 2020 | |
| Daiichi Sankyo INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.